New and updated data on the use of novel therapeutics in combination therapy in patients with newly diagnosed or relapsed/refractory multiple myeloma were presented at the 2007 meeting of the American Society of Clinical Oncology (ASCO), June 1 through 5, in Chicago, Illinois.